Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 9Squamous Cell Carcinoma of Head and Neck 3Neoplasms 3Colorectal Neoplasms 3Small Cell Lung Carcinoma 2Lung Neoplasms 2Esophageal Neoplasms 2Carcinoma, Hepatocellular 2Uterine Cervical Neoplasms 1Urothelial Cancer 1Urinary Bladder Neoplasms 1Spinocerebellar Degenerations 1Sarcoma 1Rhabdoid Tumor 1Rectal Neoplasms 1Pancreatic Adenocarcinoma 1PD-L1-selected Solid Tumors 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Chordoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Renal Cell 1Brain Neoplasms 1Advanced Solid Malignancies 1Advanced Rare Malignant Solid Neoplasm 1Advanced Liver Cancers 1

Interventions

Nivolumab 4Ipilimumab 3Specimen Handling 2Proton Therapy 2Magnetic Resonance Spectroscopy 2Cetuximab 2tazemetostat 1spartalizumab 1pembrolizumab 1nilotinib 1atezolizumab 1Zoledronic Acid 1X-Rays 1Tiragolumab 1Surveys and Questionnaires 1Radiotherapy 1Radiosurgery 1Phantoms, Imaging 1Imatinib Mesylate 1Fluorodeoxyglucose F18 1Cyclophosphamide 1CTLA-4 Antigen 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chordoma × Tiragolumab × 1 year × Clear all
NCT05286801 2026-05-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
86 enrolled
Sarcoma

Chordoma, Sarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡